Five Prime Therapeutics Inc (FPRX) Expected to Announce Earnings of -$1.07 Per Share

Equities analysts predict that Five Prime Therapeutics Inc (NASDAQ:FPRX) will post ($1.07) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Five Prime Therapeutics’ earnings. The lowest EPS estimate is ($1.50) and the highest is ($0.81). Five Prime Therapeutics posted earnings per share of ($0.63) in the same quarter last year, which would suggest a negative year over year growth rate of 69.8%. The firm is expected to issue its next quarterly earnings results after the market closes on Wednesday, May 8th.

On average, analysts expect that Five Prime Therapeutics will report full-year earnings of ($3.99) per share for the current year, with EPS estimates ranging from ($5.96) to ($3.35). For the next year, analysts forecast that the business will report earnings of ($2.95) per share, with EPS estimates ranging from ($3.67) to ($2.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.20. Five Prime Therapeutics had a negative return on equity of 44.55% and a negative net margin of 281.64%.

FPRX has been the topic of a number of analyst reports. Wedbush upgraded Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Thursday, January 17th. ValuEngine lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 4th. Cowen reiterated a “buy” rating on shares of Five Prime Therapeutics in a research report on Wednesday, February 27th. Zacks Investment Research upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, January 21st. Finally, BidaskClub upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 22nd. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Five Prime Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $24.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC bought a new stake in shares of Five Prime Therapeutics in the 4th quarter valued at about $58,000. Jane Street Group LLC bought a new stake in shares of Five Prime Therapeutics during the 4th quarter valued at about $110,000. Virtu Financial LLC bought a new stake in shares of Five Prime Therapeutics during the 4th quarter valued at about $113,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Five Prime Therapeutics by 456.2% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 10,895 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Five Prime Therapeutics during the 3rd quarter valued at about $190,000. Hedge funds and other institutional investors own 86.62% of the company’s stock.

Shares of FPRX opened at $11.91 on Monday. Five Prime Therapeutics has a 12-month low of $7.84 and a 12-month high of $19.70. The stock has a market capitalization of $429.52 million, a price-to-earnings ratio of -2.88 and a beta of 3.18.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Featured Article: Current Ratio

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.